---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016659"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:37:56.712686+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AgeX Q1 2023 net loss widens to $3.3M; cash only $0.3M; going concern flagged

## Summary
- Cash, cash equivalents and restricted cash totaled $0.3M as of March 31, 2023.
- Owed Juvenescence $33.6M in principal and origination fees; secured note line increased by $4M on May 9.
- Q1 revenue $10K (up from $5K YoY); operating expenses $2.2M vs $2.1M.
- Net loss attributable to AgeX $3.3M ($0.09 per share) vs $2.7M ($0.07) in prior year.
- Company expresses substantial doubt about ability to continue as a going concern.

## SEC filing metadata
- accession: 0001493152-23-016659
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/0001493152-23-016659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016659
- JSON: https://secwatch.observer/filing/0001493152-23-016659.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016659.txt

## Key facts
- Earnings Releases
  Serina Therapeutics, Inc. reported quarter ended March 31, 2023 results: revenue $10,000, net income $3.3 million, EPS ($0.09) per share (basic and diluted).
  - Period: quarter ended March 31, 2023
  - Revenue: $10,000
  - Net income: $3.3 million
  - EPS: ($0.09) per share (basic and diluted)
  - Result: reported results
  source text: and fund each of AgeX’s future draws of that additional amount of credit. First Quarter 2023 Operating Results Revenues: Total Revenues for the first quarter of 2023 were $10,000 as compared with $5,000 in the same period in 2022. Revenues are entirely comprised of sales of research products including stem cell products. Operating expenses: Operating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/0001493152-23-016659-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.